NURS FPX 4055 Assessment 4 Health Promotion Plan Presentation

Name

Capella university

NURS-FPX4055 Optimizing Population Health through Community Practice

Prof. Name

Date

Health Promotion Plan Presentation

Good morning and thank you for joining us. We’re grateful for the support of our community partners as we delve into a vital topic impacting adolescent and young adult health in Schwenksville, Pennsylvania: the prevention of Human Papillomavirus (HPV) infection. This presentation centers on adolescents and young adults aged 11 to 26, aligning with both SMART objectives and the national targets established by Healthy People 2030. Our agenda includes a focused exploration of HPV’s transmission, associated cancer risks, the critical timing of vaccination, and best practices for encouraging vaccine conversations within families and with healthcare professionals.

The presentation will follow a structured progression to ensure clarity and engagement. We begin with essential facts regarding HPV and its strong links to several types of cancer. Next, we examine the benefits and safety of the HPV vaccine, stressing the importance of early immunization. Attendees will be encouraged to take action by scheduling vaccinations promptly. Communication strategies will also be introduced to help individuals advocate confidently for the vaccine. Interactive activities and a knowledge check will cap the session, helping reinforce learning and assess participant progress.

Table 1: Session Segments and Corresponding Objectives

Session Segment	Objective
Key Facts on HPV	Increase understanding of HPV transmission and cancer risks
Importance of Vaccination	Explain the safety, efficacy, and urgency of vaccination
Call to Action	Motivate scheduling of HPV vaccination within 30 days
Communication Strategies	Improve participants’ ability to discuss the vaccine confidently
Engagement Activities	Reinforce learning through participation
Post-Session Assessment	Measure retention and communication preparedness

HPV spreads primarily through sexual and skin-to-skin contact. Statewide, approximately 68.7% of adolescents in Pennsylvania have received the full course of the HPV vaccine. However, this rate drops significantly in rural areas such as Schwenksville, where only 48.7% of eligible adolescents are fully vaccinated (PA.gov, 2025). These disparities contribute to higher risks of HPV-related cancers in underserved areas. Persistent infection with high-risk HPV strains, including types 16 and 18, is the leading cause of cervical, anal, and oropharyngeal cancers (Huber et al., 2021). Although most infections resolve naturally, some can result in precancerous changes or malignancy. Vaccination and routine screening play a crucial role in prevention and early detection.

Benefits and Communication Strategies

Administering the HPV vaccine during early adolescence—ideally around age 11 or 12—provides optimal immune response and long-lasting protection. The vaccine is most effective when given before any exposure to the virus (Hoes et al., 2021). Besides safeguarding against cervical cancer, which remains a leading cause of mortality among women globally, the vaccine also offers protection from other cancers, including penile, throat, and anal cancers that affect all genders (Cheng et al., 2020). Another notable benefit is the reduction of genital warts, which are both physically uncomfortable and socially stigmatized. Broad vaccine uptake contributes to community-level protection through herd immunity, lowering virus prevalence and protecting individuals who cannot be vaccinated (Xu et al., 2024).

Educating families about the HPV vaccine requires effective communication tools. Presenting credible, research-based information from authoritative sources like the Centers for Disease Control and Prevention (CDC) or World Health Organization (WHO) builds trust and encourages acceptance. Encouraging youth and caregivers to ask informed questions during doctor visits—such as inquiring about the vaccine’s long-term benefits—can initiate more meaningful conversations. It is equally important to address and correct common misconceptions, such as the myth that vaccination promotes early sexual behavior. Framing the vaccine as a cancer prevention tool rather than a behavioral endorsement helps reframe the conversation around health and safety.

Table 2: Key Benefits of HPV Vaccination

Benefit	Description
Stronger Immune Response	Early vaccination leads to more robust, long-lasting immunity
Cancer Prevention	Protects against multiple cancers in both males and females
Reduction in Genital Warts	Prevents infections that can cause physical discomfort and emotional distress
Community Immunity	Helps reduce overall transmission and protect vulnerable populations
Healthcare Cost Savings	Lowers the economic and medical burden associated with HPV-related diseases

These strategies promote informed choices and help reduce vaccine hesitancy. They empower individuals to confidently advocate for their health and contribute to better outcomes at the community level.

SMART Goals Evaluation and Alignment with Healthy People 2030

This educational initiative was structured around measurable SMART goals to evaluate its effectiveness. The first goal was to ensure that at least 90% of participants could identify three or more critical facts about HPV and its links to cancer. This was achieved, with 92.5% demonstrating a clear understanding during the quiz. A second goal focused on encouraging at least 80% of eligible individuals to commit to getting vaccinated within a month. While 75% expressed this intent, slightly below target, it remains a promising result. Lastly, the goal to increase participant confidence in discussing the HPV vaccine with healthcare providers and family was met, with 85% reporting improved communication skills.

Table 3: SMART Goals and Measured Outcomes

SMART Goal	Target	Outcome	Remarks
HPV-Cancer Knowledge	90%	92.5%	Target surpassed; solid evidence of educational impact
Vaccination Commitment	80%	75%	Slightly below goal; further parental involvement needed
Confidence in Vaccine Communication	85%	85%	Goal achieved; role-play and myth-busting recommended

While results were generally favorable, some gaps remain. For instance, a number of adolescents noted that they felt unprepared to commit to vaccination without parental input. Others expressed discomfort in addressing misinformation with peers. To address these issues in future sessions, the following enhancements are proposed: include guided family discussions during the presentation; incorporate hands-on exercises that directly challenge common myths; and extend the session duration or offer follow-up support to solidify learning and decision-making.

This program also contributes meaningfully to achieving objectives set forth by Healthy People 2030. These include increasing the proportion of vaccinated adolescents and reducing the incidence of HPV-related cancers (U.S. Department of Health and Human Services, n.d.). The session’s high levels of knowledge acquisition and improved communication readiness are aligned with these public health goals. However, the vaccination pledge gap suggests a need for continued outreach and sustained engagement strategies. Providing ongoing resources, family-inclusive initiatives, and access to up-to-date scientific data will help bridge this gap and promote lasting behavior change.

Conclusion

This health promotion presentation effectively underscored the urgency and benefits of HPV vaccination for youth and young adults in Schwenksville. Through informative content, goal-oriented planning, and participant engagement, the session elevated knowledge and communication confidence. Although some attendees require more support to finalize vaccination decisions, the program made measurable strides toward improving public health and aligning with Healthy People 2030 benchmarks. Sustained collaboration with families, schools, and healthcare providers will be essential to maintaining momentum and addressing the regional disparities in HPV vaccine coverage.

References

Cheng, L., Wang, Y., & Du, J. (2020). Human papillomavirus vaccines: An updated review. Vaccines, 8(3), 391. https://doi.org/10.3390/vaccines8030391

Hoes, J., Pasmans, H., Schurink-van ’t Klooster, T. M., van der Klis, F. R. M., Donken, R., Berkhof, J., & de Melker, H. E. (2021). HPV vaccination: Long-term effectiveness and immunity in adolescents. Vaccine, 39(9), 1319–1326. https://doi.org/10.1016/j.vaccine.2020.12.065

Huber, L. R., Liu, J., Choi, Y. S., & Garcia, S. G. (2021). Preventing cervical cancer through HPV vaccination: The role of community-based education. Journal of Women’s Health, 30(5), 645–653. https://doi.org/10.1089/jwh.2020.8623

Kassymbekova, D., Walker, T. Y., & Markowitz, L. E. (2023). Barriers to HPV vaccine uptake and strategies for overcoming them. Preventive Medicine Reports, 31, 102072. https://doi.org/10.1016/j.pmedr.2023.102072